Clinical trials: Elderly Population
COVID-19, Coronavirus Infections
Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical Trial
This clinical trial adopts a randomized, double-blind and placebo-controlled design. A total of 16000 participants are planned to be enrolled, of which, Cohort 1: 15000 participants vaccinated with ≥2 doses of inactivated…
- Trial name
- NCT05599516
- Testing
- LIBP-Rec-Vaccine, BIBP-Rec-Vaccine
- Where
- United Arab Emirates
- Volunteers
- 16,000 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
Alzheimer's Disease
Phase 1 Study Investigating Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects
To determine if treatment with HTL0009936 will lead to changes in neural activity, measured using the fMRI BOLD signal and ASL, in brain areas that are associated with spatial and working memory, learning and executive…
- Trial name
- NCT02546310
- Testing
- HTL0009936
- Where
- United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Nxera Pharma UK Limited
Influenza
Japanese Pediatric H5N1 Vaccine Study
The purpose of this study is to obtain immunogenicity and safety data of an H5N1 pandemic influenza vaccine in a Japanese pediatric population aged 6 months to 17 years
- Trial name
- NCT01911754
- Testing
- H5N1 (Pre-)Pandemic Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated)
- Where
- 2 sites in Japan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
COVID-19
A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy Adults
This is a phase III, randomized, observer-blind, active-controlled, parallel group, multi-center study to compare the immunogenicity and safety of a preventive COVID-19 vaccine EuCorVac-19 to ChAdOx1 in healthy adults aged 18…
- Trial name
- NCT05572879
- Testing
- EuCorVac-19, ChAdOx1 nCoV-19
- Where
- Philippines
- Volunteers
- 2,600 people, healthy volunteers welcome
- Sponsor
- EuBiologics Co.,Ltd
Lichen Simplex Chronicus
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)
This is a parallel, Phase 3, 2-arm study for treatment. The purpose of this study is to measure improvement in pruritus with dupilumab subcutaneous injections compared with placebo injections in male and female participants aged…
- Trial name
- NCT06687980
- Testing
- Dupilumab
- Where
- 63 sites in United States, Argentina and 15 more
- Volunteers
- 138 people
- Sponsor
- Sanofi
Cystic Fibrosis
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation
The purpose of this study was to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis aged 6 to 11 years who have the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR)…
- Trial name
- ENVISION (NCT00909727)
- Testing
- Ivacaftor
- Where
- 29 sites in United States, Australia and 5 more
- Volunteers
- 52 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Haemophilus Influenzae Type B Infection
Clinical Trial of Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine
This trial is a randomized, partially blinded, positively controlled phase I clinical study. A total of 160 persons aged 18-59 years, 1-5 years, 6-11 months and 2 months (60-89 days) will be recruited into the trial, and the…
- Trial name
- NCT06621654
- Testing
- Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine, Haemophilus Influenzae Type b Conjugate Vaccine
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Epidemic Meningitis, Meningococcal Vaccines
Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 3-5 Months
The goal of this clinical trial is to evaluate the immunogenicity, safety, and immune persistence of the primary series of an investigational group ACYW135 meningococcal conjugate vaccine, as well as the immunogenicity and safety…
- Trial name
- NCT07505810
- Testing
- experimental vaccine, Active Comparator vaccine
- Where
- 2 sites in China
- Volunteers
- 880 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Pneumococcal Vaccines
Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults
The objective of the study is to evaluate the safety, tolerability and immunogenicity of a single injection of VAX-31 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 50 to 64 years of age in Stage 1.
- Trial name
- NCT06151288
- Testing
- 31 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine
- Where
- 25 sites in United States
- Volunteers
- 1,015 people, healthy volunteers welcome
- Sponsor
- Vaxcyte, Inc.
The Elderly (≥ 70 Years) With Essential Hypertension
Fimasartan in the Senior Subjects
The objective of this study is to confirm the noninferiority of the blood pressure lowering effect of fimasartan and evaluate its safety compared to perindopril in the elderly with essential hypertension.
- Trial name
- FITNESS (NCT03246555)
- Testing
- Fimasartan or Fimasartan/Hydrochlorothiazide, Perindopril or Perindopril/Indapamide
- Where
- South Korea
- Volunteers
- 241 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
COVID-19
Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents
This study is a multi-center and open design, phase Ⅳ clinical trial of an inactivated SARS-CoV-2 vaccine (CoronaVac) manufactured by Sinovac Research and Development Co., Ltd.The purpose of this study is to evaluate the safety…
- Trial name
- NCT04992208
- Testing
- Experimental Group
- Where
- China
- Volunteers
- 31,041 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Cystic Fibrosis
A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor
This is a Phase 3, randomized, double-blind, ivacaftor-controlled, parallel-group, multicenter study of tezacaftor in combination with ivacaftor in subjects aged 12 years and older with CF who are heterozygous for the…
- Trial name
- NCT02412111
- Testing
- Ivacaftor, Tezacaftor/Ivacaftor
- Where
- 68 sites in United States, Australia and 8 more
- Volunteers
- 156 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Influenza
H5N1 Vaccine Study in Japanese Elderly Population Aged 65 Years and Older
The purpose of this study is to obtain immunogenicity and safety data of an H5N1 pandemic influenza vaccine in a Japanese elderly population aged 65 years and older.
- Trial name
- NCT01774032
- Testing
- H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation
- Where
- 2 sites in Japan
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
COVID-19, SARS-CoV-2 Infection
A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines
The study is a randomized, double-blind, and positive-controlled Phase III booster study. It will evaluate the immunogenicity and safety of one dose of SCTV01C or SCTV01E as booster compared with either one dose of Sinopharm…
- Trial name
- NCT05323461
- Testing
- SCTV01C, SCTV01E, Sinopharm inactivated COVID-19 vaccine
- Where
- United Arab Emirates
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Covid19
Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine
The study is an observer-blind, randomized, controlled prospective intervention study of Phase I. The primary objective is To evaluate the safety of the SARS-CoV-2 protein subunit recombinant vaccine within 7 days after each dose.
- Trial name
- NCT05067894
- Testing
- SARS-CoV-2 Protein Subunit Recombinant Vaccine, SARS-CoV-2 Inactivated Vaccine
- Where
- Indonesia
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Gastroesophageal Reflux Disease (GERD)
Phase 3/Safety & Efficacy of Esomeprazole in Infants
The purpose of this study is to look at the improvement of a once a day dose of esomeprazole for reducing the signs and symptoms of infants with gastroesophageal reflux disease (GERD).
- Trial name
- NCT00468559
- Testing
- Open Label Run In Esomeprazole, Double Blind Esomeprazole
- Where
- 25 sites in United States, France and 2 more
- Volunteers
- 98 people
- Sponsor
- AstraZeneca
Pulmonary Arterial Hypertension, Children
A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension.
This is a clinical research study designed to evaluate sildenafil for the treatment of Pulmonary Arterial Hypertension in children, aged 1 to 17 years.
- Trial name
- NCT00159913
- Testing
- Sildenafil citrate
- Where
- 41 sites in United States, Brazil and 15 more
- Volunteers
- 235 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Arthritis, Psoriatic
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
This is a study to confirm the clinical efficacy and safety of sonelokimab compared with placebo in the treatment of adults with active psoriatic arthritis who have had a previous inadequate response or intolerance to anti-tumor…
- Trial name
- IZAR-2 (NCT06641089)
- Testing
- Sonelokimab, Risankizumab
- Where
- 143 sites in United States, Bulgaria and 9 more
- Volunteers
- 600 people
- Sponsor
- MoonLake Immunotherapeutics AG
Influenza
Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.
The present study OVX836-006 aims principally to: Confirm feasibility of the concomitant administration of the vaccines under normal clinical conditions, i.e.
- Trial name
- NCT05734040
- Testing
- OVX836 480µg, Fluarix Tetra, Afluria Quad
- Where
- 9 sites in Australia
- Volunteers
- 478 people, healthy volunteers welcome
- Sponsor
- Osivax
COVID-19, SARS-CoV-2 Infection
The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine.
The objective of this study is to evaluate the safety, tolerability, and immunogenicity of SCTV01C in healthy population aged ≥18 years previously vaccinated with inactivated COVID-19 vaccine.
- Trial name
- NCT05043285
- Testing
- SCTV01C
- Where
- United Arab Emirates
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.